Water

Water

SCHEMBL2863467

O.O.O=S(=O)([O-])c1ccccc1.[Na+]

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.52
DUSP3 P51452 1/20 0.52
PTPN5 P54829 1/20 0.52
PTPN11 Q06124 1/20 0.52
CA2 P00918 4/20 0.48
CA1 P00915 3/20 0.48
ALDH1A1 P00352 3/20 0.48
CA12 O43570 3/20 0.48
CA9 Q16790 3/20 0.48
TDP1 Q9NUW8 2/20 0.48
HSD17B10 Q99714 1/20 0.48
CA3 P07451 1/20 0.48
CA4 P22748 1/20 0.48
CA6 P23280 1/20 0.48
CA5A P35218 1/20 0.48
CA7 P43166 1/20 0.48
PLA2G7 Q13093 1/20 0.48
CA13 Q8N1Q1 1/20 0.48
CA14 Q9ULX7 1/20 0.48
CA5B Q9Y2D0 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL6448903 1.00 HTR6 (0.52) HTR6DUSP3PTPN5PTPN11CA2
SCHEMBL597671 0.97 HTR6 (0.55) HTR6DUSP3PTPN5PTPN11CA2
SCHEMBL6740023 0.97 HTR6 (0.55) HTR6DUSP3PTPN5PTPN11CA2
SCHEMBL3409456 0.97 HTR6 (0.55) HTR6DUSP3PTPN5PTPN11CA2
SCHEMBL1981609 0.97 HTR6 (0.55) HTR6DUSP3PTPN5PTPN11CA2
SCHEMBL28929 0.97 HTR6 (0.55) HTR6DUSP3PTPN5PTPN11CA2
SCHEMBL11761400 0.97 HTR6 (0.55) HTR6DUSP3PTPN5PTPN11CA2
SCHEMBL28477667 0.97 HTR6 (0.55) HTR6DUSP3PTPN5PTPN11CA2
Water SCHEMBL8617713 0.94 HTR6 (0.52) HTR6DUSP3PTPN5PTPN11CA2
Water SCHEMBL22581636 0.94 ALDH1A1 (0.55) HTR6DUSP3PTPN5PTPN11CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112023726-B Low-energy-consumption high-flux reverse osmosis membrane and preparation method and application thereof 万华化学集团股份有限公司 2022-07-12 CN claimed
CN-109912470-B Synthetic method of 3- (benzenesulfonyl) propionic acid 苏州华道生物药业股份有限公司 2021-01-05 CN claimed
CN-119855576-A Dental product with reduced extrusion force 舒万诺知识产权公司 2025-04-18 CN disclosed
CN-112055579-B One-component dental adhesive composition for fixing dental composite materials 3M创新有限公司 2024-01-23 CN disclosed
CN-113164444-A DOCK1 inhibiting compounds and uses thereof 国立大学法人九州大学 2021-07-23 CN disclosed
CN-109912470-B Synthetic method of 3- (benzenesulfonyl) propionic acid 苏州华道生物药业股份有限公司 2021-01-05 CN disclosed
CN-112055579-A One-component dental adhesive composition for fixing dental composite material 3M创新有限公司 2020-12-08 CN disclosed
CN-110678160-A Dental adhesive composition, its preparation and use 3M创新有限公司 2020-01-10 CN disclosed
US-20160040067-A1 LIQUID CRYSTAL COMPOUND HAVING BUTENE-BONDING GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC PETROCHEMICAL CORPORATION (JP) 2016-02-11 US disclosed
US-8580146-B2 Liquid crystal compound, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2013-11-12 US disclosed
EP-2206695-B1 TETRA- OR PENTA-CYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT JNC CORP (JP) 2013-09-18 EP disclosed
CN-1854135-B Heteronuclear compound with dicyandiamide connection and its medicinal use LI WEIZHANG 2013-06-12 CN disclosed
US-20120193577-A1 LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC PETROCHEMICAL CORPORATION (JP) 2012-08-02 US disclosed
US-8187494-B2 Four- or five-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device JNC CORPORATION (JP) 2012-05-29 US disclosed
US-20100309402-A1 FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE CHISSO CORPORATION (JP) 2010-12-09 US disclosed
EP-2206695-A1 TETRA- OR PENTA-CYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT Chisso Corporation (JP) 2010-07-14 EP disclosed
CN-1854135-A Heteronuclear compound with dicyandiamide connection and its medicinal use LI WEIZHANG (CN) 2006-11-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100309402-A1 FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE KIF23, HCN3, FZD7 HTR6 2022/4885DUSP3 708/4885PTPN5 902/4885
US-20160040067-A1 LIQUID CRYSTAL COMPOUND HAVING BUTENE-BONDING GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE CXCR1, PIEZO1, L1CAM HTR6 3350/4885DUSP3 4800/4885PTPN5 3966/4885
US-20120193577-A1 LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE KIF23, MARK3, CCND3 HTR6 2870/4885DUSP3 493/4885PTPN5 2131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.